rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Vincent Aurentz

Director

Company insider

Files Form 4 as: Director, Inhibikase Therapeutics; Director, Longboard Pharmaceuticals; Executive VP and CBO, Arena Pharmaceuticals; Chief Business Officer, EPIRUS Biopharmaceuticals.

Every Form 4 they filed

In numbers

Trades disclosed
68
Buys
2
Sells
4
Bought
$18K
Sold
$5.6M
Companies
4
Companies where not an officer
2
First trade
9 Nov 2015
Last trade
26 Jun 2026
Last filed
30 Jun 2026

Companies traded

Where they are an officer
Arena PharmaceuticalsOfficer · last 11 Mar 20220 buys · 4 sells
EPIRUS BiopharmaceuticalsOfficer · last 27 May 20162 buys · 0 sells
Everywhere else they filed: board seats, 10% stakes, other companies
IKT Inhibikase TherapeuticsDirector · Biotechnology · last 26 Jun 20260 buys · 0 sells
Longboard PharmaceuticalsDirector · last 2 Dec 20240 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
26 Jun 2026filed 30 Jun 2026IKT Inhibikase Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—155,000 at $0.00filing
26 Jun 2026filed 30 Jun 2026IKT Inhibikase Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—155,000 at $0.00filing
21 Feb 2026filed 24 Feb 2026IKT Inhibikase TherapeuticsBiotechnologySEC FORM 4 Code D—255,299 at $0.00filing
21 Feb 2026filed 24 Feb 2026IKT Inhibikase TherapeuticsBiotechnologySEC FORM 4 Code D—255,299 at $0.00filing
30 Jun 2025filed 2 Jul 2025IKT Inhibikase Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—108,176 at $0.00filing
21 Feb 2025filed 2 Jul 2025IKT Inhibikase Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—134,427 at $0.00filing
21 Feb 2025filed 25 Feb 2025IKT Inhibikase Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—134,427 at $0.00filing
2 Dec 2024filed 2 Dec 2024Longboard Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—12,367filing
2 Dec 2024filed 2 Dec 2024Longboard Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—7,214filing
2 Dec 2024filed 2 Dec 2024Longboard Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—12,367filing
2 Dec 2024filed 2 Dec 2024Longboard Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—12,500filing
2 Dec 2024filed 2 Dec 2024Longboard Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—22,500filing
23 May 2024filed 24 May 2024Longboard Pharmaceuticalsoption or derivativeSEC FORM 4 Code A—22,500 at $0.00filing
25 May 2023filed 26 May 2023Longboard Pharmaceuticalsoption or derivativeSEC FORM 4 Code A—12,500 at $0.00filing
24 May 2022filed 31 May 2022Longboard Pharmaceuticalsoption or derivativeSEC FORM 4 Code A—12,367 at $0.00filing
11 Mar 2022filed 11 Mar 2022Arena Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—45,000filing
11 Mar 2022filed 11 Mar 2022Arena Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—77,000filing
11 Mar 2022filed 11 Mar 2022Arena Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—94,976filing
11 Mar 2022filed 11 Mar 2022Arena Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—75,000filing
11 Mar 2022filed 11 Mar 2022Arena Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—70,000filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed6

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.